Home » Stocks » TTOO

T2 Biosystems, Inc. (TTOO)

Stock Price: $2.48 USD 0.29 (13.24%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $2.47 -0.01 (-0.40%) Feb 24, 5:56 PM
Market Cap 343.26M
Revenue (ttm) 13.41M
Net Income (ttm) -50.93M
Shares Out 147.79M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $2.48
Previous Close $2.19
Change ($) 0.29
Change (%) 13.24%
Day's Open 2.28
Day's Range 2.26 - 2.64
Day's Volume 7,517,125
52-Week Range 0.24 - 3.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

LEXINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to pa...

The Motley Fool - 2 weeks ago

The diagnostic test maker's panels could help to combat the spread of new coronavirus variants.

InvestorPlace - 2 weeks ago

TTOO stock is climbing on Friday after T2 Biosystems announced its Covid-19 test can detect the Brazilian strain. What should you know?

GlobeNewsWire - 2 weeks ago

Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis

GlobeNewsWire - 3 weeks ago

LEXINGTON, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, announced today that it issued an ind...

GlobeNewsWire - 4 weeks ago

Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG

Seeking Alpha - 1 month ago

T2 has been a huge beneficiary of the COVID-19 pandemic, as hospitals take a second look at its revolutionary diagnostic technology. A 300% revenue gain is projected by Wall Street for 2021 vs...

The Motley Fool - 1 month ago

Investors are excited about the prospects of the company's COVID-19 diagnostic test.

Benzinga - 1 month ago

BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tisleliz...

Other stocks mentioned: AMRX, BGNE
InvestorPlace - 1 month ago

T2 Biosystems (TTOO) stock is on the rise Tuesday following positive news concerning testing for new strains of the novel coronavirus. The post TTOO Stock: 10 Things to Know About T2 Biosystem...

Business Insider - 1 month ago

As the COVID-19 virus mutates into different variants, one small-cap diagnostics company says their test can detect the mutated strains: T2 Biosystems. T2 Biosystems soared as much as 49% in T...

GlobeNewsWire - 1 month ago

Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.

Zacks Investment Research - 1 month ago

T2 Biosystems (TTOO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Insider Monkey - 2 months ago

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and anal...

Seeking Alpha - 3 months ago

A struggling diagnostics platform is benefiting from Sars-COVID-2 tailwinds. Its sars-COVID-2 test is accelerating the uptake of its diagnostic platform.

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to pa...

Seeking Alpha - 3 months ago

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

T2 Biosystems (TTOO) delivered earnings and revenue surprises of 20.00% and 32.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 months ago

Shares of T2 Biosystems (NASDAQ:TTOO) fell 10% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 74.19% over the past year to ($0.08...

GlobeNewsWire - 3 months ago

Total revenues increase by 213% on record high quarterly product sales Total revenues increase by 213% on record high quarterly product sales

Zacks Investment Research - 3 months ago

T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financia...

Zacks Investment Research - 4 months ago

Is (TTOO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 4 months ago

Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Re...

Zacks Investment Research - 5 months ago

Is (TTOO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 5 months ago

Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus Summit will raise awareness and highlight the critica...

GlobeNewsWire - 5 months ago

Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients

GlobeNewsWire - 5 months ago

The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument

Zacks Investment Research - 5 months ago

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Other stocks mentioned: CERS, KMDA
Benzinga - 6 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, CERS, GRFS, KMDA, LMNL, SONN, THMO
Zacks Investment Research - 6 months ago

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

Seeking Alpha - 6 months ago

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of T2 Biosystems (NASDAQ: TTOO) decreased 7.49% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 6 months ago

LEXINGTON, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the ...

Benzinga - 6 months ago

T2 Biosystems (NASDAQ: TTOO) announces its next round of earnings this Tuesday, August 11.

GlobeNewsWire - 6 months ago

LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that its Board of Director...

Zacks Investment Research - 6 months ago

In the latest trading session, T2 Biosystems (TTOO) closed at $1.66, marking a +1.84% move from the previous day.

GlobeNewsWire - 6 months ago

LEXINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to ...

GlobeNewsWire - 6 months ago

LEXINGTON, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financ...

Zacks Investment Research - 6 months ago

T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.

Zacks Investment Research - 7 months ago

In the latest trading session, T2 Biosystems (TTOO) closed at $1.62, marking a +0.62% move from the previous day.

Zacks Investment Research - 7 months ago

In the latest trading session, T2 Biosystems (TTOO) closed at $1.33, marking a -0.75% move from the previous day.

24/7 Wall Street - 7 months ago

T2 Biosystems Inc. (NASDAQ: TTOO) solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.

GlobeNewsWire - 7 months ago

The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument

GlobeNewsWire - 7 months ago

Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement a...

Zacks Investment Research - 8 months ago

Is (TTOO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 8 months ago

LEXINGTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that on June 16, 2020 it r...

GlobeNewsWire - 8 months ago

Three new appointments add significant clinical and commercialization experience and expand board diversity Three new appointments add significant clinical and commercialization experience and...

About TTOO

T2 Biosystems, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as we... [Read more...]

Industry
Diagnostics & Research
IPO Date
Aug 7, 2014
CEO
John Sperzel
Employees
118
Stock Exchange
NASDAQ
Ticker Symbol
TTOO
Full Company Profile

Financial Performance

In 2019, T2 Biosystems's revenue was $8.34 million, a decrease of -20.62% compared to the previous year's $10.50 million. Losses were -$59.01 million, 15.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for T2 Biosystems stock is "Strong Buy." The 12-month stock price forecast is 3.18, which is an increase of 28.23% from the latest price.

Price Target
$3.18
(28.23% upside)
Analyst Consensus: Strong Buy